当前位置：
X-MOL 学术
›
Ther. Adv. Med. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2020-03-04 , DOI: 10.1177/1758835920907534 Martyna Borowczyk 1 , Ewelina Szczepanek-Parulska 2 , Szymon Dębicki 2 , Bartłomiej Budny 2 , Małgorzata Janicka-Jedyńska 3 , Lidia Gil 4 , Frederik A Verburg 5 , Dorota Filipowicz 2 , Elżbieta Wrotkowska 2 , Blanka Majchrzycka 2 , Andrzej Marszałek 6 , Katarzyna Ziemnicka 2 , Marek Ruchała 2
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2020-03-04 , DOI: 10.1177/1758835920907534 Martyna Borowczyk 1 , Ewelina Szczepanek-Parulska 2 , Szymon Dębicki 2 , Bartłomiej Budny 2 , Małgorzata Janicka-Jedyńska 3 , Lidia Gil 4 , Frederik A Verburg 5 , Dorota Filipowicz 2 , Elżbieta Wrotkowska 2 , Blanka Majchrzycka 2 , Andrzej Marszałek 6 , Katarzyna Ziemnicka 2 , Marek Ruchała 2
Affiliation
Patients with differentiated thyroid cancer (DTC) may present with unfavorable prognostic factors. The five-year cancer-specific survival for patients presenting with distant metastases is only 40%1,2 as these patients frequently become refractory to radioiodine3,4 despite the advent of tyrosine kinase inhibitors (TKI).5
中文翻译：
FLT3突变在滤泡性甲状腺癌中的高发生率：晚期疾病患者的潜在治疗靶点
分化型甲状腺癌 (DTC) 患者可能存在不利的预后因素。远处转移患者的五年癌症特异性生存率仅为 40% 1,2 ，因为尽管酪氨酸激酶抑制剂 (TKI) 的出现，这些患者经常变得对放射性碘耐药3,4 。5
更新日期：2020-04-21
中文翻译：
FLT3突变在滤泡性甲状腺癌中的高发生率：晚期疾病患者的潜在治疗靶点
分化型甲状腺癌 (DTC) 患者可能存在不利的预后因素。远处转移患者的五年癌症特异性生存率仅为 40% 1,2 ，因为尽管酪氨酸激酶抑制剂 (TKI) 的出现，这些患者经常变得对放射性碘耐药3,4 。5
京公网安备 11010802027423号